BTK has become something of a hot target in MS research, and Biogen's deal follows Sanofi's $3.7 billion takeover of Principia Biopharma and its drug tolebrutinib, which is already in phase 3 ...

He highlighted that revenue from launch products offset declines in the multiple sclerosis (MS) franchise, leading to core pharmaceutical growth for the first time in four years. Biogen aims to ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Biogen today (NASDAQ:BIIB) discovers, develops, and sells therapies for neurological and neurodegenerative diseases like multiple sclerosis (MS) and Alzheimer’s disease. A company’s long-term ...

Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new building in Kendall Square in 2028, consolidating its various branches and ...

“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” said Governor Maura Healey, in a statement. “We are thrilled to see them ...

Commonwealth Equity Services LLC trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.2% in the ...

So my MS team, which is doing phenomenally well this ... the other lesson learned is relationships matter. So where we deployed Biogen representatives as an overlay to the Eisai team.